EXTENDED REPORT

Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis

Dag Leonard,1 Elisabet Svenungsson,2 Johanna Dahlqvist,3 Andrei Alexsson,1 Lisbeth Årlestig,4 Kimberly E Taylor,5 Johanna K Sandling,1 Christine Bengtsson,4 Martina Frodlund,6 Andreas Jönsen,7 Susanna Eketjäll,8 Kerstin Jensen-Urstad,9 Iva Gunnarsson,2 Christopher Sjöwall,6 Anders A Bengtsson,7 Majia-Leena Eloranta,1 Ann-Christine Syvänä,10 Solbritt Rantapää-Dahlqvist,4 Lindsey A Criswell,5 Lars Rönnblom1

ABSTRACT

Objectives Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have increased risk of cardiovascular disease (CVD). We investigated whether single nucleotide polymorphisms (SNPs) at autoimmunity risk loci were associated with CVD in SLE and RA. Methods Patients with SLE (n=1045) were genotyped using the 200K Immunochip SNP array (Illumina). The allele frequency was compared between patients with and without different manifestations of CVD. Results were replicated in a second SLE cohort (n=1043) and in an RA cohort (n=824). We analysed publicly available genetic data from general population, performed electrophoretic mobility shift assays and measured cytokine levels and occurrence of antiphospholipid antibodies (aPLs). Results We identified two new putative risk loci associated with increased risk for CVD in two SLE populations, which remained after adjustment for traditional CVD risk factors. An IL19 risk allele, rs17581834(T) was associated with stroke/myocardial infarction (MI) in SLE (OR 2.3 (1.5 to 3.4), P=8.5x10⁻⁵) and RA (OR 2.5 (1.5 to 4.6), P=3.8x10⁻⁵), meta-analysis (OR 2.5 (2.0 to 2.9), P=3.5x10⁻⁵), but not in population controls. The IL19 risk allele affected protein binding, and SLE patients with the risk allele had increased levels of plasma-IL10 (P=0.004) and aPL (P=0.01). An SRPS4-AS1 risk allele, rs799454(S) was associated with stroke/transient ischaemic attack in SLE (OR 1.7 (1.3 to 2.2), P=2.5x10⁻³) but not in RA. The SRPS4-AS1 risk allele is an expression quantitative trait locus for four genes. Conclusions The IL19 risk allele was associated with stroke/MI in SLE and RA, but not in the general population, indicating that shared immune pathways may be involved in the CVD pathogenesis in inflammatory rheumatic diseases.

INTRODUCTION

Patients with systemic lupus erythematosus (SLE) have a 2–10 fold increased risk of cardiovascular disease (CVD) compared with the general population, with the highest relative risk in younger patients and highest absolute risk in older individuals.1–3 Women with SLE in the age of 35–45 years have a 50-fold increased risk of myocardial infarction (MI) compared with the general population.4 Death related to active disease and infections have decreased, but mortality related to CVD shows no such decline.5 Instead, a slight increase in standardised mortality ratio due to vascular diseases has been reported.6 Today SLE is acknowledged as a unique risk factor for CVD by the American Heart Association.

Traditional risk factors cannot fully explain the increased risk for CVD in SLE, and a number of SLE-related risk factors have been identified, such as antiphospholipid antibodies (aPL) and renal impairment.6–10 Genetic predisposition is an important risk factor for SLE, and different risk genes are also connected to CVD. We have previously shown that a variant of interferon regulatory factor 8 (IRF8)11 is associated with development of ischaemic heart disease in SLE and that a variant of signal transducer and activator of transcription 4 (STAT4) is associated with aPL and ischaemic stroke.12 Other risk genes shown to be associated with CVD in SLE include mannose-binding lectin, C reactive protein and HLA-DRB1*04/*13–15 Recently, a large international association study identified 24 new SLE risk loci using Immunochip genotype data.16,17 In the present study, we examined if single nucleotide polymorphisms (SNPs) analysed by the Immunochip were associated with CVD in two large SLE cohorts and investigated possible functional effects of associated gene variants. We also investigated if identified risk gene variants were associated with CVD in patients with rheumatoid arthritis (RA) and in the general population.

PATIENTS AND METHODS

Patients and controls

The discovery cohort included 1045 patients with SLE from rheumatology clinics in Sweden. All patients fulfilled ≥4 American College of Rheumatology (ACR) 1982 criteria for SLE.18 The replication cohort included 1043 patients with SLE from the University of California, San Francisco (UCSF) Lupus Genetics project.19 All patients completed an extensive questionnaire, and the SLE diagnosis was confirmed by medical record review according to
the ACR criteria. The SLE patients were all of European decent, and age at diagnosis was similar in both populations, but patients in the replication cohort were younger at follow-up and had less CVD events (Table 1). In the discovery cohort, the average age at first stroke/transient ischaemic attack (TIA) was 52 years and at first stroke/MI was 54 years (online supplementary table S1). Information regarding stroke and TIA was available for 814 patients in the SLE discovery cohort and data regarding TIA, and angina was not available for the replication cohort. Patients with RA (n=824) all fulfilled the 1987 RA classification criteria (online supplementary table S2). Healthy blood donors (n=2711) were recruited as previously described. 21 Publicly available data from the CARDioGRAMplusC4D Consortium22 and the International Stroke Genetics Consortium23 were used for analyses of CVD in the general population (online supplementary methods). All participants gave their informed consent.

### Table 1 Clinical characteristics of the patients with SLE

|                                | Discovery cohort (Sweden) | Replication cohort (UCSF) | P values |
|--------------------------------|---------------------------|---------------------------|----------|
| Number of patients             | 1045                      | 1043                      |          |
| Female                         | 910 (87)                  | 959 (92)                  | <0.001   |
| Age at diagnosis (year)        | 36±16                     | 35±14                     | 0.12     |
| Age at study (year)            | 51±16                     | 44±13                     | <0.001   |
| PE/DVT                         | 153 (15)                  | 91 (10)                   | <0.001   |
| MI/angina*                     | 107 (10)                  | 39 (4)                    | <0.001   |
| Stroke/TIA†                    | 96 (12)                   | 55 (5)                    | <0.001   |
| Stroke/MI†                     | 133 (16)                  | 84 (8)                    | <0.001   |
| Antiphospholipid antibodies§    | 292(31)                   | 374(41)                   | <0.001   |
| ACR criteria                   |                           |                           |          |
| 1) Malar rash                  | 576 (55)                  | 424 (41)                  | <0.001   |
| 2) Discoid rash                | 243 (23)                  | 60 (6)                    | <0.001   |
| 3) Photosensitivity            | 699 (67)                  | 816 (78)                  | <0.001   |
| 4) Oral ulcers                 | 243 (23)                  | 282 (27)                  | 0.06     |
| 5) Arthritis                   | 823 (79)                  | 727 (70)                  | <0.001   |
| 6) Serositis                   | 459 (44)                  | 269 (26)                  | <0.001   |
| 7) Renal disorder              | 349 (33)                  | 237 (23)                  | <0.001   |
| 8) Neurological disorder       | 104 (10)                  | 89 (9)                    | 0.26     |
| 9) Haematological disorder     | 630 (60)                  | 638 (61)                  | 0.72     |
| 10) Immunological disorder     | 711 (68)                  | 640 (61)                  | 0.001    |
| 11) Positive ANA               | 1026 (98)                 | 954 (91)                  | <0.001   |
| SD† median (range)             | 1 (0–13)                  | NA                        |          |
| BILD** median (range)          | NA                        | 2 (0–13)                  |          |

Categorical variables were compared with χ² test and continuous variables by Student’s unpaired t-test.

*Data regarding angina were available only for the discovery cohort.

†Missing data for 231 patients in the discovery cohort, data regarding TIA were only available for the discovery cohort.

§Discovery cohort, at least one positive test for anticardiolipin (IgM or IgG) or anti-β2 glycoprotein-I (IgG), data available for 952 patients. Replication cohort, at least one positive test for lupus anticoagulant, anticardiolipin (IgM or IgG) or anti-β2 glycoprotein-I (IgM or IgG), data available for 907 patients.

** BILD data available for 514 patients.

ACR criteria, American College of Rheumatology classification criteria for SLE (manifestations until end of follow-up), ANA, antinuclear antibodies BILD, Brief Index of Lupus Damage; DVT, deep vein thrombosis; MI, myocardial infarction; NA, data not available; PE, pulmonary embolism; SDI, Systemic Lupus International Collaborating Clinics /ACR damage index for SLE; SLE, systemic lupus erythematosus; TIA, transient ischaemic attack; UCSF, University of California, San Francisco.

### Genotyping and quality control

Genotyping of the SLE discovery cohort, SLE replication cohort and the RA cohort was performed using the Illumina Immunochip (for quality control, see supplementary methods). 16, 17, 24

### Statistical analysis

A logistic regression model with sex and disease duration included as covariates was used to test association between SNPs and CVD in the SLE discovery cohort. For the American–European population sex, disease duration and the first principal component for population stratification were included as covariates. The identification of SNPs associated with CVD in SLE included three steps. First, the four CVD variables were tested for association with the Immunochip SNPs using data from the discovery cohort. Next, the top 100 associated SNPs per variable were tested for association with CVD in the SLE replication cohort, and SNPs not achieving nominal significance (P>0.05) were excluded. Finally, SNPs with meta-analysis P<0.001 were chosen as candidates for functional follow-up. The identified interleukin 19 (IL19) and signal recognition particle 54 – antisense 1 (SRP54–AS1) SNPs were analysed in the RA cohort, including sex and disease duration as covariates. Resulting significant variants were included in a cross-disease meta-analysis of SLE and RA. In this meta-analysis, P<1.0×10⁻⁶ adjusting for 48 000 independent SNPs on the Immunochip were considered significant. In other analyses, p values <0.05 were considered significant. For more information on statistical and bioinformatic analyses, see supplementary methods.

### Functional analysis

Electrophoretic mobility shift assays (EMSA) were performed using nuclear extract from Jurkat, LCL, K562, HUVEC cell lines and peripheral blood mononuclear cells (PBMCs) from healthy individuals (supplementary methods). Expression quantitative trait loci (QTLs) were analysed using GTEx datasets, and IL19 (R&D Systems), IL10 (Mesoscale Discovery) and aPL levels were measured (supplementary methods). 12

### Carotid ultrasound

Ultrasound scans were performed as previously described. 26

### RESULTS

**Identification of risk loci for CVD in SLE**

The allele frequencies of 137 213 SNPs were compared between patients with SLE in the discovery cohort with and without CVD. Initially, we asked if there are general risk genes for CVD in SLE and consequently analysed ischaemic stroke and/or MI (stroke/MI) as one variable. Next, we looked for subtype-specific risk gene variants analysing MI and/or angina (MI/angina) and ischaemic stroke and/or TIA (stroke/TIA) separately. Finally, venous thrombosis defined as pulmonary embolism and/or deep vein thrombosis (PE/DVT) was analysed. We identified eight SNPs at three different loci demonstrating an association with CVD in both the discovery cohort and in the replication cohort, all reaching P<0.001 in the meta-analysis (Tables 2 and 3). The IL19 risk alleles were associated with stroke/MI, the SRP54–AS1 risk alleles, and the IL7R receptor (IL7R) risk alleles were associated with stroke/TIA. Functional studies did not indicate the IL7R risk allele to be important for CVD development (see
supplementary file). No SNPs were associated with MI/angina or PE/DVT (data not shown).

THE IL19 LOCUS

Three SNPs in the IL19 gene (rs74148801, rs17581834 and rs11119598) showed an association with stroke/MI in both SLE cohorts and in the meta-analysis (OR 2.3 (1.5 to 3.4), P = 8.5 × 10⁻⁵; table 2). All three SNPs are located in intron 1 of the IL19 gene and are in high linkage disequilibrium (LD) with each other (1000 Genomes, r² = 1) (figure 1A). The association between stroke/MI and the IL19 risk allele remained significant when adjusting for known cardiovascular risk factors in a multivariable regression analysis (OR 2.03 (1.07 to 3.84), P = 3.09 × 10⁻⁵; online supplementary table S4). The IL19 risk allele was not associated with SLE per se (online supplementary table S5), the ACR criteria (online supplementary table S6)¹⁸ or the SLICC-DI (SDI) (OR 1.30 (0.94 to 1.79), P = 0.12).²⁴ There was no association between the IL19 risk allele and intima-media thickness (IMT) (0.059 vs 0.063 mm, P = 0.92) or presence of carotid plaque (27% vs 21%, P = 0.47) in a subgroup of patients with SLE (n = 202) examined by carotid ultrasound.

To clarify the function of the IL19 risk allele, we initially performed EMSAs to investigate effects on transcription factor (TF) binding at the locus. Nuclear extract from Jurkat cells stimulated with PMA/ionomycin or PBMC stimulated with interferon-α (IFN-α) demonstrated binding of a protein to the reference allele (C) but not the risk/alternative allele (T) (figure 1B,C). Nuclear extract from unstimulated Jurkat cells or PBMCs displayed no differential binding between the two alleles. Next, protein expression of genes located at the IL19 locus, including IL19 and IL10 (figure 1A), were examined. Serum-IL19 was measured in 394 SLE patients, but no significant difference between patients with and without the IL19 risk allele was observed (24% vs 19%, P = 0.41). Plasma-IL10 was measured in 243 patients and patients with the IL19 risk allele more often had elevated IL10 compared with patients without the IL19 risk allele (50% vs 22%, P = 0.0038). SLE patients with high IL10 more often had elevated levels of anticardiolipin (aCL) IgM antibodies compared with patients with low IL10 (31% vs 14%, P = 0.01). Given these results, we measured the levels of aPL in 781 patients with SLE and observed an association between the IL19 risk allele and elevated levels of aCL IgG (P = 0.002), aCL IgM (P = 0.002), anti-β₂ glycoprotein-I (anti-β₂GPI) IgG (P = 0.0004) and antiprophthrombin (n = 494) IgG (P = 0.04) antibodies. Furthermore, the IL19 risk allele showed an association with positive lupus anticoagulant (LA; n = 311) test (P = 0.03).

The Signal recognition particle 54 – antisense 1 locus

Three SNPs (rs7994545, rs1712349 and rs712308) located in the SRP54-AS1 gene and in high LD with each other (r² = 1) (figure 2A) were associated with stroke/TIA (table 3) with an OR of 1.7 (1.3 to 2.2), P = 2.5 × 10⁻⁵ in the SLE meta-analysis. When including the SRP54-AS1 risk allele together with traditional cardiovascular risk factors, the association remained (OR 1.65 (1.15 to 2.37), P = 6.10 × 10⁻⁵; online supplementary table S7). The SRP54-AS1 risk allele was not associated with SLE (online supplementary table S5), the ACR criteria, levels of aPL, IMT or carotid plaque (data not shown, all P > 0.05).

EMSA analysis using nuclear cell extract from Jurkat, LCL, K562 and PBMCs showed protein binding to the SRP54-AS1 risk locus but no distinct allele specific difference (data not shown). According to chromatin immunoprecipitation with DNA sequencing (ChIP-Seq) data from the ENCODE project,
Signal transducer and activator of transcription 1 (STAT1) binds to the SRP54-AS1 locus. As STAT1 is crucial for IFN-α signalling, we tested recombinant STAT1 in the EMSA and showed that STAT1 is one of the proteins binding at the SRP54-AS1 risk locus, with a lower affinity to the risk allele (figure 2B). According to GTEx data, the three SNPs at the SRP54-AS1 locus affect the expression of signal recognition particle 54 (S54), protein phosphatase 2 regulatory subunit B gamma (PPP2R3C), SRP54-antisense 1 (SRP54-AS1) and family with sequence similarity 177 member A1 (FAM177A1) in multiple tissues (online supplementary figure 1A–D). These genes are all located close to the SRP54-AS1 risk locus (figure 2A). In addition, the SNP rs712306, in high LD ($r^2=0.7$), with the SRP54-AS1 risk allele showed differential expression of FAM177A1 in the artery wall ($P=3.9\times10^{-6}$) (GTEx, online supplementary figure 1E). The IL-19 and the SRP54-AS1 loci in RA and in the general population

In order to investigate if the six identified CVD risk variants were confined to patients with SLE, or could constitute a risk factor for patients with other inflammatory rheumatic diseases, we compared the allele frequencies of the risk gene variants in RA patients with, and without, CVD (table 4). Results show that all 3 IL19 gene variants were associated with stroke/MI in SLE and that allele frequencies of the risk gene variants in patients with and without stroke/MI were similar in RA and SLE (table 4). In addition, the IL19 risk alleles showed association with stroke/TIA in RA (OR 2.8 (1.4 to 5.6), $P=3.8\times10^{-3}$). The SRP54-AS1 risk allele did not show an association with CVD in RA (data not shown). When including patients with SLE and RA in a meta-analysis, the association with stroke/MI...
remained (OR 2.45 (1.96 to 2.94), P = 3.5 × 10^{−7}, after Bonferroni adjustment for 48 000 independent SNP on the Immuno- chip P \text{adj} = 0.017). Publicly available data of individuals in the general population showed no association between the \text{IL19} and \text{SRP54-AS1} risk variants and ischaemic stroke or coronary artery disease (see supplementary results).

**DISCUSSION**

The objective of the present study was to investigate possible associations between genetic variation and CVD in SLE, and we identified two new risk loci, namely \text{IL19} and \text{SRP54-AS1}. The \text{IL19} risk locus is located in an interleukin gene cluster coding for several cytokines, including \text{IL19} and \text{IL10}. Several SNPs in this region have previously been associated with SLE \text{^27,28} and CVD in both the general population \text{^29,30} and in a small SLE study of 52 individuals. \text{^31} However, none of these earlier identified SNPs are in high LD with the SNPs at the \text{IL19} risk locus identified here, and none of the previously described SNPs were associated with CVD in our dataset. The observation that our identified risk gene variants were not associated with CVD in the general population suggests that there exist at least partly different underlying mechanisms behind CVD in SLE and the general population. The clinical picture for patients with and without the \text{IL19} risk allele did not differ regarding the ACR criteria \text{^18} or the SDI. \text{^24} Thus, the higher frequency of strokes and MIs in the group with the risk allele is not caused by a more severe SLE disease. Furthermore, when adjusting for known CVD risk factors, the \text{IL19} risk allele association remained. Thus, our results suggest that the \text{IL19} risk allele is an independent risk factor for stroke and MI in SLE patients with European decent. However, none of these earlier identified SNPs are in high LD with the SNPs at the \text{IL19} risk locus identified here, and none of the previously described SNPs were associated with CVD in our dataset. The observation that our identified risk gene variants were not associated with CVD in the general population suggests that there exist at least partly different underlying mechanisms behind CVD in SLE and the general population. The clinical picture for patients with and without the \text{IL19} risk allele did not differ regarding the ACR criteria \text{^18} or the SDI. \text{^24} Thus, the higher frequency of strokes and MIs in the group with the risk allele is not caused by a more severe SLE disease. Furthermore, when adjusting for known CVD risk factors, the \text{IL19} risk allele association remained. Thus, our results suggest that the \text{IL19} risk allele is an independent risk factor for stroke and MI in SLE patients with European decent. The observation that the \text{IL19} risk allele also was associated with stroke/MI in patients with RA, but not in the general population, furthermore suggest that the gene variants identified could be confined to patients with an inflammatory rheumatic disease, or at least SLE and RA. However, this assumption needs to be confirmed in studies with patients with other diagnoses.

The \text{IL19} risk locus is a putative binding site for several TFs and is located in a region of open chromatin with predicted enhancer function in LCLs and CD4 and CD8-positive T cells. \text{^32,33} In our EMSA analyses, we observed differential binding to the \text{IL19} risk allele of nuclear extract from non-activated Jurkat cells. Competitor DNA is unlabelled DNA probes as competitors in 100-fold excess. Ref.=reference allele (C); Alt.=alternative allele (T). dbSNP, The Short Genetic Variations database; EMSA, electrophoretic mobility shift assay; SNP, single nucleotide polymorphisms; SRP54-AS1, signal recognition particle 54 – antisense 1; STAT1, signal transducer and activator of transcription 1; TIA, transient ischaemic attack.

**Table 4 \text{IL19} SNPs associated with stroke/MI in rheumatoid arthritis**

| SNP        | Locus | M/m | MAF   | OR (95% CI) | P values |
|------------|-------|-----|-------|-------------|----------|
| rs17581834 | IL19  | C/T | 0.12/0.05 | 2.7 (1.5 to 5.2) | 1.1 × 10^{−3} |
| rs11119598 | IL19  | A/G | 0.11/0.05 | 2.5 (1.4 to 4.6) | 3.1 × 10^{−3} |
| rs74148801 | IL19  | C/T | 0.11/0.05 | 2.6 (1.4 to 4.8) | 2.1 × 10^{−3} |

Logistic regression analysis between the three \text{IL19} risk variants and stroke/MI in rheumatoid arthritis (genetic data available for 71 RA patients with and 753 without stroke/MI after RA-disease onset). \text{IL}, interleukin; MAF, minor allele frequency for cases/controls; M/m, major/minor alleles; MI, myocardial infarction; P, p value unadjusted; SNP, single nucleotide polymorphism.
activated Jurkat cells. Because extract from unstimulated cells did not show differential binding to the site, cell activation or high levels of IFN-α as observed in SLE seems to be a requirement for the expression of the relevant protein. Publicly available data identified IKAROS family zinc finger 3 (IKZF3) as one possible TF with differential binding to the two alleles. IKZF3 is important for regulation of B cell differentiation, and recently a SNP in the promoter region of IKZF3 was shown to be associated with SLE. Interestingly, expression of IKZF3 is regulated by IRF8, a TF involved in IFN signalling and associated with CVD in SLE. In conclusion, our EMSA analyses suggest that the IL19 risk locus functions as a cell activation-dependent regulatory region and that the IL19 risk allele abrogates the binding of a TF induced by IFN-α or T cell activation.

To examine if the IL19 risk allele affects gene expression, we used data from the GTEx project but found no difference in RNA expression. Next, we went on to analyse protein expression of genes located in the same topologically associated domain and measured IL19 and IL10 levels in the patients with SLE. Similar to previously identified SNPs with long-range functional connections, we found that the intronic IL19 risk allele affects expression of the IL10 gene, located at a distance of 30 kb from the IL19 locus. As IL10 is known to stimulate B cells and antibody production, we measured levels of aPL and found indeed elevated levels of both aCL and αPL-GPI as well as LA in patients with the IL19 risk allele. As presence of aPLs is a known risk factor for CVD, especially stroke, these results suggest that the IL19 risk locus exerts a regulatory effect on IL10 expression, enhancing production of prothrombotic aPL by B cells. However, as both aPL and the IL19 risk allele remained significantly associated with stroke/MI in the multivariable regression analysis other mechanisms are also possible. Recently, it was reported that IL10 enhances IFN-α-mediated endothelial progenitor cell (EPC) dysfunction and that levels of IL10 correlated with EPC function in SLE but not in healthy controls. Thus, there are several mechanisms whereby IL10 could exert a negative effect on the circulatory system in SLE with implications for cardiovascular pathology.

The SRP54-AS1 locus was found to be associated with stroke/TIA in SLE. This locus was not associated with a more severe SLE disease, aPLs or subclinical atherosclerosis suggesting a novel mechanism of action. Published ChIP-Seq data indicate that the SRP54-AS1 locus is located in a region with enhancer/promoter function in CD4, CD8, CD19 and CD14 positive cells with several TFs potentially binding to the locus, including STAT1. In fact, we demonstrated that STAT1 displays a lower affinity to the alternative allele. This is interesting given the enhanced expression of STAT1 observed in PBMCs of patients with SLE and its role in intracellular signalling following binding of IFN-α to the type I IFN receptor. According to the GTEx database, FAM177A1, SRP54, PPP2R3C and SRP54-AS1 are differentially expressed in individuals with the SRP54-AS1 risk allele. Noteworthy, FAM177A1 is differentially expressed in the artery wall and has previously been associated with neurogenetic disorders. Because FAM177A1 has unknown functions, further studies are needed to determine possible mechanisms connecting FAM177A1 and stroke/TIA in SLE.

The strength of the present study is the large number of patients with SLE and RA investigated, the detailed information regarding CVD events available and that cytokine levels and aPLs were measured in a large number of patients. Furthermore, the Immunochip has approximately 48,000 independent SNPs when LD is considered, and a conservative p value threshold for significance of meta-analysis would be 1×10−6. When including both the patients with SLE and RA in the meta-analysis, the statistical analysis reached this level of significance. Limitations include that the patients in the replication cohort were younger at follow-up resulting in fewer CVD events compared with the discovery cohort and that aPL and stroke data were missing for 20% of patients in the discovery cohort. In addition, we did not have data regarding lipid levels for the patients but identified risk genes have no reported function in lipid metabolism.

In summary, we have identified two potential risk genes of importance for development of CVD in SLE and for IL19 possibly also in RA. SLE patients with the IL19 risk allele, associated with stroke/MI, more often had high IL10 and elevated levels of aPL. The SRP54-AS1 risk allele, associated with stroke/TIA in SLE, was found to likely affect expression of a number of genes. Strikingly, both identified loci seem to affect gene regulation, rather than protein structure. We could also show that the IL19 gene variant is associated with stroke/MI in both SLE and RA but not in the general population, which suggests the existence of shared mechanisms in the development of CVD in patients with inflammatory rheumatic diseases and this assumption deserves further studies.

Author affiliations
1Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
2Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
3Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
4Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
5University of California, San Francisco, Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, San Francisco, California, USA
6Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
7Department of Rheumatology, Skåne University Hospital, Lund, Sweden
8Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Integrated Cardio Metabolic Centre, Karolinska Institutet, Stockholm, Sweden
9Department of Clinical Physiology, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
10Department of Medical Sciences, Science for Life Laboratory, Molecular Medicine, Uppsala University, Uppsala, Sweden

Acknowledgements We would like to thank the patients and healthy volunteers for participating, Lisbeth Fedex, Rezvan Kiani and Karolina Tandre for technical assistance and collecting blood samples. Genotyping of the discovery and RA cohort was performed by the SNP53EQ Technology Platform, Uppsala.

Contributors DL, LR, JKS and AA designed the study. JD, SE, M-LE and DL performed the experiments. KJ-U performed the carotid ultrasound examinations. DL, ES, CB, KE, MF, IG, CS, AAB, SR-D, LAC and LR collected the data. AA, KET, LA and DL performed the statistical analysis. DL, AA, KET, JKS, LR, ES, JD, A-CS, LAC, SR-D and M-LE analysed the data. DL, JKS, JD and LR wrote the manuscript. All authors approved the final version of the manuscript.

Funding This project was funded by the Swedish Research Council for Medicine and Health (D0283001, A0258801, E0226301 and E0395401), Knut and Alice Wallenberg Foundation (2011.0073), AstraZeneca-Science for Life Laboratory Research Collaboration Grant (DISSECT), Swedish Society of Medicine and Ingegerd Johansson donation, Swedish Rheumatism Foundation, King Gustaf V’s 80-year Foundation, Torsten Söderberg Foundation, Uppsala County Council and Uppsala University Hospital (ALF), Stockholm County Council (ALF), Uppsala University, Swedish Heart-Lung Foundation, Selander Foundation, Agnes and Matt Rudberg Foundation, Gustaf Prim Foundation and COMBINE. Work related to the UCF5 cohort was supported by NIH grants U1-TR-00004, P60-AR-053308 and R01-AR-48400.

Competing interests None declared.

Patient consent Obtained.

Ethics approval The regional ethics committee in Uppsala, Sweden and the local ethics committees.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,
REFERENCES

1. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221–5.

2. Bengtsson C, Ohman ML, Nived O, et al. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 2012;21:452–9.

3. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77–95.

4. Marás S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408–15.

5. Björnäld L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J Rheumatol 2004;31:713–9.

6. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2950–7.

7. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 2011;57:1404–23.

8. Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 2014;47:67–76.

9. Kaplan MJ, Salmon JF. How does interferon-α insult the vasculature? Let me count the ways. Arthritis Rheum 2011;63:334–6.

10. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708–19.

11. Leonard D, Svenungsson E, Sandling JK, et al. Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ Cardiovasc Genet 2013;6:255–63.

12. Svenungsson E, Gustafsson J, Leonard D, et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010;69:834–40.

13. Øihlsenschläger T, Gared P, Madson HO, et al. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004;351:260–7.

14. Szalai AJ, Alarcón GS, Calvo-Alén J, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology 2005;44:864–8.

15. Lundström E, Gustafsson JT, Jönsen A, et al. HLA-DRB1*04/*13 alleles are associated with systemic lupus erythematosus and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2013;72.

16. Langefeld CD, Ainsworth HC, Cunningham Graham DS, et al. Transcardiac measurement and genetic load in systemic lupus erythematosus. Nat Commun 2017;8:16021.

17. Cortes A, Brown MA. Promise and pitfalls of the ImmuneCheck. Arthritis Res Ther 2011;13:101.

18. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1988;25:1271–7.

19. Thorburn CM, Prokunina-Ølsson L, Sterba KA, et al. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes Immun 2007;8:279–87.

20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:319–24.

21. Almlof JC, Alexsson A, Ingenberg-Kreuz L, et al. Novel risk genes for systemic lupus erythematosus predicted by random forest classification. Sci Rep 2017;7:6236.

22. CARDioGRAMplusC4D. CARDioGRAMplusC4D Consortium. http://www.cardiogramplusc4d.org/data-downloads/ (accessed 22 Dec 2017).

23. International Stroke Genetics Consortium (ISGC). Welcome to the International Stroke Genetics Consortium. http://cerebrovascularportal.org/ (accessed 11 Jan 2018).

24. Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012;44:1336–40.

25. G. Tex Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580–5.

26. Gustafsson JT, Heritz Lindberg M, Gunnarssson I, et al. Excess atherosclerosis in systemic lupus erythematosus: A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. PLoS One 2017;12:e0174572.

27. Gavada V, Sandling JK, Hom G, et al. A large-scale replication study identifies TNPI1, PRDM12, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009;41:1226–33.

28. Zhou M, Ding L, Peng H, et al. Association of the interleukin-10 gene polymorphism (-1082A/G) with systemic lupus erythematosus: a meta-analysis. Lupus 2013;22:128–35.

29. Kumar P, Yadav AK, Misra S, et al. Role of Interleukin-10 (-1082A/G) gene polymorphism with the risk of ischamic stroke: a meta-analysis. Neurol Res 2016;38:823–30.

30. Wang BJ, Liu J, Geng J, et al. Association between three interleukin-10 gene polymorphisms and coronary artery disease risk: a meta-analysis. Int J Clin Exp Med 2015;8:17842–55.

31. Fei GZ, Svenungsson E, Frostegård J, et al. The A-10871G-10 allele is associated with cardiovascular disease in SLE. Atherosclerosis 2004;177:49–14.

32. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57–74.

33. Fingerman IM, McDaniel L, Zhang X, et al. NCBI Epigenomics: a new public resource for exploring epigenetic datasets. Nucleic Acids Res 2011;39:D908–D912.

34. Thomas-Chollier M, Hutfon A, Heiring M, et al. Transcription factor binding predictions using TRAP for the analysis of ChIP-seq data and regulatory SNPs. Nat Protoc 2011;6:1860–9.

35. Lessard CJ, Adrianto I, Ice JA, et al. Identification of IRF8, TME399A, and IKF3- HPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet 2012;90:648–60.

36. Ma S, Pothak S, Thiru L, et al. Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development. Blood 2008;111:1396–403.

37. Sjöstrand M, Johansson A, Agrawal L, et al. The Expression of BAFF Is Controlled by IRF Transcription Factors. J Immunol 2016;196:91–6.

38. The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions. BioRxiv, 2017. http://biorxiv.org/ content/early/2017/02/27/112268. (accessed 27 Feb 2017).

39. Smedo S, Tena JJ, Kim KH, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature 2014;507:371–5.

40. Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839–44.

41. Salo MA, Lindqvist E, Immonen J, et al. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Rep 2016;34:21–4.

42. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:319–24.

43. Almlof JC, Alexsson A, Ingenberg-Kreuz L, et al. Novel risk genes for systemic lupus erythematosus predicted by random forest classification. Sci Rep 2017;7:6236.

44. Correia AL, Alarcón GS, Calvo-Alén J, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1988;31:319–24.

45. Gladman DD, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.

46. Hafizy L, Turgun L, Gansky SA, et al. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res 2013;65:1170–7.